Lutris Pharma is a clinical-stage biopharmaceutical company dedicated to
enhancing the effectiveness of anti-cancer therapies while improving patients’
quality of life. The company is developing LUT014, a first-in-class,
topical B-Raf inhibitor designed to reduce the severe dermal toxicity
associated with Epidermal Growth Factor Receptor (EGFR) inhibitors and
radiation therapy—adverse effects that often compromise treatment adherence. Given
the oncology-related indications, Lutris Pharma has received FDA waivers,
enabling an accelerated regulatory pathway toward approval. With a robust
pipeline addressing significant unmet needs in oncology and beyond, Lutris is
poised to transform supportive cancer care and improve treatment outcomes.